The Renal Protective Effects of Angiotensin II Receptor Blockers in Type 2 Diabetes Mellitus

2004 ◽  
Vol 38 (10) ◽  
pp. 1731-1738 ◽  
Author(s):  
James D Coyle ◽  
Stephanie F Gardner ◽  
C Michael White
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Angiotensin Ii ◽  
Angiotensin Ii Receptor Blockers ◽  
Protective Effects ◽  
Angiotensin Ii Receptor ◽  
Receptor Blockers

Angiotensin-II Receptor Antagonist Alleviates Non-alcoholic Fatty Liver in KKAy Obese Mice with Type 2 Diabetes

2006 ◽  
Vol 34 (3) ◽  
pp. 297-302 ◽  
Author(s):  
F Yu ◽  
T Takahashi ◽  
J Moriya ◽  
K Kawaura ◽  
J Yamakawa ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Angiotensin Ii ◽  
Obese Mice ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonist ◽  
Alcoholic Fatty Liver ◽  
Adiponectin Mrna

We examined the effects of the angiotensin-II receptor antagonist candesartan on non-alcoholic fatty liver (NAFL) and circulating adiponectin concentrations in KKAy obese mice with type 2 diabetes mellitus. The KKAy mice were randomly assigned to receive either candesartan at a once-daily dose of 10 mg/kg ( n = 5) or placebo ( n = 5). The differences in liver weight, histological evaluation of hepatic lipid infiltration, serum adiponectin concentration and hepatic adiponectin mRNA levels between the two groups were determined on day 7 after treatment was initiated. Candesartan-treated mice demonstrated significantly lower liver weights and reduced lipid droplets in hepatic cells compared with control mice. The circulating adiponectin levels and hepatic expression of adiponectin mRNA were significantly higher in candesartan-treated mice than control mice. These results suggest that candesartan might alleviate NAFL through elevation of circulating adiponectin levels in KKAy obese mice with type 2 diabetes mellitus.

Sign in / Sign up

Export Citation Format

Share Document